Immunohistochemistry validation demonstrated higher expression levels of FLRT3 (11) in cluster Tumor-P, SLAMF8 (12) in clusters Tumor-IM/IN, and IL13RA2 (13) in cluster Tumor-IM, aligning with the aforementioned results (Figure 5C). The gene discussed is IL13RA2; the disease is neoplasm.